Therefore, the levels of serum FGF2 may have prognostic significance in these cancers, and quantification of FGF2 may provide an indirect, non-invasive way to monitor patients with high risk of relapse from solid and hematological tumors (Tables 2 and 3). This evidence concerns the gene FGF2 and hematopoietic and lymphoid cell neoplasm.